Tempest Therapeutics, Inc. (TPST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Stephen R. Brady J.D., LLM | CEO, President & Director | 923.24k | -- | 1970 |
| Mr. Nicholas Maestas | VP of Strategy & Finance and Secretary | 465.43k | -- | 1981 |
| Dr. Samuel Whiting M.D., Ph.D. | Executive VP & Chief Medical Officer | 667.65k | -- | 1966 |
| Mr. Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | -- | -- | 1988 |
| Ms. Lindsay Young | Head of Human Resources | -- | -- | -- |
| Dr. Sharon Sakai Ph.D., RAC | Head of Regulatory & Quality | -- | -- | -- |
Tempest Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Corporate Governance
Upcoming Events
August 8, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
Tempest Therapeutics, Inc. Earnings Date